Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of approximately $5.9 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), with a market capitalization of approximately $5.9 billion, has been making waves in the pharmaceutical industry with its flagship drug Rezdiffra, ...

I’ve no history of nosebleeds, but over the past five weeks, I’ve had five. The first three times, the bleeding stopped after ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

“Rezdiffra demonstrated broad, sustained efficacy across multiple noninvasive parameters at two years of treatment. A high, statistically significant percentage of patients with CSPH or probable CSPH ...

Their medication, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and is currently undergoing a Phase 3 trial for compensated MASH cirrhosis.

CONSHOHOCKEN, Pa., May 10, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...